Cerebrum Therapeutics develops First in Class small chemical molecules for the treatment of neurodegeneratives diseases and brain injuries based on proprietary molecules and technology plateforms.
Our first program is targeting the Tauopathy indication, a rare disease with orphan drug designation. Our hit and backup candidates are at 2,5 years from clinical trial.
We want to become a reference player in these two therapeutics fields in 6 years.